Please assess the completion status of the following clinical trial:

Trial Title: Study To Evaluate The Efficacy And Safety Of Oral PF-06651600 And PF-06700841 In Subjects With Moderate To Severe Crohn's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male and/or female subjects 18 years to 75 years of age~2. Documented diagnosis of ileal, ileocolonic, or colonic CD with a minimum disease duration of 3 months, as determined by endoscopic and histopathology assessment.~3. Endoscopic confirmation of active disease with total SES CD total score of at least 7. For isolated ileal disease, SES CD total score should be at least 4.~4. An average daily liquid/soft stool frequency (SF) greater than or equal to 2.5 or daily abdominal pain (AP) greater than or equal to 2.0.~5. Must have inadequate response to, loss of response to, or intolerance to at least one conventional therapy for CD:~   •Steroids; Immunosuppressants (azathioprine \[AZA\], 6 MP, or methotrexate \[MTX\]); Anti TNF inhibitors (infliximab, adalimumab,certolizumab); Anti integrin inhibitors (eg, vedolizumab); Anti IL 12/23 inhibitor (ustekinumab).~6. Subjects currently receiving the following treatment for CD are eligible providing they have been on stable doses as described below:~   * Oral corticosteroids (prednisone or equivalent up to 25 mg/day; budesonide up to 9 mg/day). Stable dose for at least 2 weeks prior to baseline. If oral corticosteroids have been recently discontinued, they must have been stopped at least 2 weeks prior to baseline. Decreases in steroid use due to AEs are allowed.~  * Oral 5 ASA or sulfasalazine are allowed providing that the dose is stable for at least 4 weeks prior to baseline.~  * Crohn's disease related antibiotics are allowed providing that the dose is stable for at least 4 weeks prior to baseline. If antibiotics are stopped prior to baseline, they must be discontinued at least 4 days prior to baseline.~Exclusion Criteria:~1. Diagnosis of indeterminate colitis, microscopic colitis, ischemic colitis, infectious colitis, radiation colitis, diverticular disease, ulcerative colitis (UC), or clinical findings suggestive of UC.~2. Presence of active (draining) fistulae or intra abdominal or perineal abscesses.~3. Strictures with obstructive symptoms.~4. Short bowel syndrome.~5. History of bowel perforation requiring surgical intervention within the past 12 months.~6. Previous bowel surgery resulting in an existing stoma. Subjects who have a j pouch are excluded, as a j pouch can result in a stoma.~7. History of bowel surgery within 6 months prior to baseline.~8. Subjects displaying clinical signs of fulminant colitis or toxic megacolon.~9. Subjects with primary sclerosing cholangitis.~10. Subjects with evidence of colonic adenomas, dysplasia or neoplasia.~11. Abnormal findings on the chest x ray film such as presence of tuberculosis (TB), general infections, heart failure, or malignancy.~12. Any history of either untreated or inadequately treated latent or active TB infection, current treatment for active or latent TB infection or evidence of currently active TB by chest x ray, residing with or frequent close contact with individual(s) with active TB.~13. Subjects receiving the following therapies within the time period described below or expected to receive any of these therapies during the study period:~    1. \>9 mg/day of oral budesonide or \>25 mg/day of prednisone or equivalent oral systemic corticosteroid dose within 2 weeks prior to baseline.~   2. IV, IM (parenteral), or topical (rectal) treatment of 5 ASA or corticosteroid enemas/suppositories within 2 weeks prior to baseline.~   3. Azathioprine, 6 mercaptopurine, or methotrexate within 2 weeks prior to baseline.~   4. Anti TNF inhibitors (or biosimilars thereof) as described below:~       * Infliximab within 8 weeks prior to baseline;~      * Adalimumab within 8 weeks prior to baseline;~      * Certolizumab within 8 weeks prior to baseline;~   5. Anti integrin inhibitors (eg, vedolizumab) within 8 weeks prior to baseline.~   6. Ustekinumab within 8 weeks prior to baseline.~   7. Interferon therapy within 8 weeks prior to baseline.~   8. Subjects with prior treatment with lymphocyte depleting agents/therapies within 1 year prior to baseline (eg, CamPath\[alemtuzumab\], alkylating agents \[eg, cyclophosphamide or chlorambucil\], total lymphoid irradiation, etc).~   9. Subjects who have received rituximab or other selective B lymphocyte depleting agents within 1 year prior to baseline.~   10. Subjects previously receiving leukocyte apheresis, including selective lymphocyte, monocyte, or granulocyte apheresis, or plasma exchange within 6 months prior to baseline.~   11. Other marketed immunosuppressants or biologics with immunomodulatory properties within 3 months prior to baseline.~   12. Subjects who have received other JAK inhibitors within 3 months prior to baseline.~   13. Subjects who have not responded to or have been intolerant of other JAK inhibitors.~   14. Other investigational procedures(s) or product(s), such as immunosuppressants used in transplantation (eg, mycophenolate mofetil, cyclosporine, rapamycin, or tacrolimus) or live (attenuated) vaccine within 30 days prior to baseline.~        14) Subjects with history of thrombotic event(s), including deep venous thrombosis (DVT), and known inherited conditions that predispose to hypercoagulability.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- PF-06700841 or placebo (Type: EXPERIMENTAL): None
- PF-06651600 or placebo (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).